State Key Laboratory of Medical Molecular Biology, Haihe Laboratory of Cell Ecosystem, Department of Physiology, Institute of Basic Medical Sciences and School of Basic Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Front Immunol. 2023 Feb 2;14:1117658. doi: 10.3389/fimmu.2023.1117658. eCollection 2023.
Esophageal squamous cell carcinoma (ESCC) is one of the most common and lethal malignant diseases. Immunotherapy has been widely studied and has exhibited potential in ESCC treatment. However, there are only a portion of ESCC patients have benefited from immunotherapy. We herein identified immunotherapeutic response-related signatures (IRRS) and evaluated their performance in ESCC prognosis and immunotherapeutic responsiveness.
We constructed an IRRS using the gene expression data of 274 ESCC patients based on y -30significantly differentially expressed genes, which were compared responders and non-responders from various patient cohorts treated with immunotherapy. Survival analysis was performed in both the GSE53625 and TCGA-ESCC cohorts. We also explored the differences in the tumor microenvironment between the high-IRRS and low-IRRS score groups using single-cell data as a reference. Three immunotherapy cohorts were used to verify the value of the IRRS in predicting immunotherapy response.
Twelve immunotherapy-related genes were selected to construct a signature score and were validated as independent prognostic predictors for patients with ESCC. Patients with high IRRS scores exhibited an immunosuppressive phenotype. Therefore, patients with low IRRS scores may benefit from immunotherapy.
IRRS score is a biomarker for immunotherapy response and prognosis of ESCC.
食管鳞状细胞癌（ESCC）是最常见和最致命的恶性疾病之一。免疫疗法已得到广泛研究，并在 ESCC 治疗中显示出潜力。然而，只有一部分 ESCC 患者从中受益。我们在此确定了免疫治疗反应相关特征（IRRS），并评估了它们在 ESCC 预后和免疫治疗反应性方面的表现。
我们基于 y -30 个差异表达基因，使用 274 名 ESCC 患者的基因表达数据构建了一个 IRRS，这些基因在来自不同免疫治疗患者队列的应答者和非应答者之间进行了比较。在 GSE53625 和 TCGA-ESCC 队列中进行了生存分析。我们还使用单细胞数据作为参考，探索了高 IRRS 和低 IRRS 评分组之间肿瘤微环境的差异。三个免疫治疗队列用于验证 IRRS 在预测免疫治疗反应中的价值。
选择了 12 个与免疫治疗相关的基因来构建特征评分，并验证其为 ESCC 患者独立的预后预测因子。IRRS 评分高的患者表现出免疫抑制表型。因此，IRRS 评分低的患者可能受益于免疫治疗。
IRRS 评分是 ESCC 免疫治疗反应和预后的生物标志物。
